Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

Vaccination and administration of monoclonal antibody cocktails are effective tools to control the progression of infectious diseases and to terminate pandemics such as COVID-19. However, the emergence of SARS-CoV-2 mutants with enhanced transmissibility and altered antigenicity requires broad-spect...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Hongyu, Yuan, Xin-Yong, Cabral, Teresa, Manguiat, Kathy, Robinson, Alyssia, Wood, Heidi, Grant, Chris, McQueen, Peter, Westmacott, Garrett, Beniac, Daniel R., Lin, Lisa, Carpenter, Michael, Kobasa, Darwyn, Gräfenhan, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572761/
https://www.ncbi.nlm.nih.gov/pubmed/34762975
http://dx.doi.org/10.1016/j.antiviral.2021.105206
Descripción
Sumario:Vaccination and administration of monoclonal antibody cocktails are effective tools to control the progression of infectious diseases and to terminate pandemics such as COVID-19. However, the emergence of SARS-CoV-2 mutants with enhanced transmissibility and altered antigenicity requires broad-spectrum therapies. Here we developed a panel of SARS-CoV-2 specific mouse monoclonal antibodies (mAbs), and characterized them based on ELISA, Western immunoblot, isotyping, and virus neutralization. Six neutralizing mAbs that exhibited high-affinity binding to SARS-CoV-2 spike protein were identified, and their amino acid sequences were determined by mass spectrometry. Functional assays confirmed that three mAbs, F461G11, F461G15, and F461G16 neutralized four variants of concern (VOC): B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) These mAbs are promising candidates for COVID-19 therapy, and understanding their interactions with virus spike protein should support further vaccine and antibody development.

Ejemplares similares